TIDES USA, 2026!
Learn how we can support you from research innovation to GMP excellence!
Join our team as we exhibit and present at TIDES USA in Boston, MA. We invite you to visit us at booth #910 to say hello.
What, where, and when?
This is a LIVE IN-PERSON EVENT
What: TIDES USA
Where: Hynes Convention Center, Boston MA, Booth #910
When: 11 – 14 May, 2026
Schedule your meeting: pharma.usa@croda.com
Discover how Croda Pharma can support your manufacturing excellence – from innovation to best practices.
Super Refined™ pharmaceutical excipients
WORKSHOP
Optimizing GAP Peptide Synthesis for Tirzepatide Fragments
The Next Wave of Innovation in Peptide Manufacturing Technologies
Monday, May 11th, 11:10am – 11:40am
Discover more about our GAP-PS with Cole Seifert, PhD, Research Manager, and its ability to unlock SPPS-like capability and operability in solution phase.
In this talk we will cover…
1. Understanding the GLP-1 Supply Challenge
a. Understand the challenges driving GLP-1 drug substance supply bottlenecks and the limitations of traditional technologies
2. Introducing Tag-Assisted Peptide Synthesis (TAPS)
a. Discuss potential and current limitations of TAPS technologies
b. Understand barriers to wider TAPS adoption as a solution to the supply chain challenges
3. GAP-PS and Solvent Anchoring Advantages
a. Discuss solvent anchoring technology, how it improves solubility control, and how it enhances capability and operational efficiency in GAP-PS
b. Detailed example data on TZP fragments demonstrate the effectiveness of this technology.
c. Improved sustainability profile vs current methods.
TECHNICAL POSTER
GAP Peptide Synthesis: Enabling Efficient One‑Pot TA‑LPPS of Tirzepatide Fragments
Tuesday May 12th – Thursday May 14th during the networking breaks
Explore new data with David Ndaleh, PhD, on GAP-PS as a scalable, greener platform for complex peptide manufacturing.
Presentation
Supporting Clients from Pre-Clinic to Commercial: Using the Wigman Model to Strategize GMP Process Development
Spotlight Luncheon Presentation 5
Tuesday, May 12th, 12:05pm – 12:35pm
Discover how we can support your journey from pre-clinic through to commercial scale up with Amy Druschitz, Technical Business Development Manager.
1. Understanding GMP Starting Material Risk Assessment
a. Understand the importance of evaluating regulatory starting materials within GMP process development.
2. Applying a Structured Risk Assessment Model
a. Describe how Croda’s Lipid Center of Excellence uses a quantitative, multi-factor risk assessment framework to evaluate materials and processes.
3. Enabling Faster, More Transparent Commercialization Decisions
a. Explain how a science-based, regulatory-justifiable approach improves transparency, aligns development strategy, and accelerates commercialization.
Tackling peptide manufacturing?
Peptide therapeutics are critical for a range of pathologies. Their recent uptake as a treatment for obesity has seen a surge in global awareness and demand. Unfortunately, peptide supply cannot keep pace and current production methods are unable to meet the desired volume. GAP-PS is an emerging synthesis technology that provides a sustainable and cost-effective solution to this tremendous supply challenge.
MORE evidence. Same innovation > Get the NEW data on our GAP-PS peptide manufacturing offerings.
Download our latest data
Request a meeting today below!
Event type: Conference
Tides USA
Each year, the TIDES conference scientific agenda includes 200+ of the industry's top scientists to present the latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC/manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products. Stop by our booth #910, our workshop on May 11th at 11:10am, our spotlight luncheon on May 12th at 12:05pm, our technical poster, and more! We will be available to discuss your projects and answer questions! Schedule your meeting with us today and discover how we can support your development needs.
New
Avanti™ DSPE-PEG2000 Amine
DSPE-PEG(2000) Amine from Avanti™ is a (PEG) 2000-modified, DSPE-anchored phospholipid bearing a terminal primary amine, enabling versatile formulation conjugation strategies and surface...
.jpg&mn=healthcare&w=768&xr=0&yr=0&xfp=6&yfp=6&hash=D55CC0B64FAF40DE483409164D9504BE19C138999FEC74AA)
Avanti™ DSPE-PEG(2000) Maleimide
DSPE PEG(2000) Maleimide is a functionalized PEG lipid that enhances ligand-mediated targeted drug delivery by facilitating bioactive molecule conjugation.
How we empower biologics delivery
